Oct. 1 , 2007 - Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced the start of a Phase 2 clinical trial evaluating the Company's PYY3-36 Nasal Spray in obese patients. The study will enroll approximately 500 obese patients for a six-month, randomized, placebo-controlled dose ranging study with weight loss as the primary endpoint... Nastech Pharmaceutical's Press Release -
Tuesday, October 2, 2007
Nastech Pharmaceutical , Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
Oct. 1 , 2007 - Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced the start of a Phase 2 clinical trial evaluating the Company's PYY3-36 Nasal Spray in obese patients. The study will enroll approximately 500 obese patients for a six-month, randomized, placebo-controlled dose ranging study with weight loss as the primary endpoint... Nastech Pharmaceutical's Press Release -